Real-world Daptomycin Use in Chinese ICUs

Completed

• Conditions: Daptomycin; Real-world Study; Intensive Care Unit

• Registration Number: NCT03588637
• Lead Sponsor: West China Hospital

Brief Summary

Analyze the effectiveness and safety of Daptomycin(Jiangsu Hengrui Medicine Co., Ltd) in Gram-positive infections in Chinese Intensive Care Units by using the real-world data platform, https://rws.scccmqc.com. Patients who received at least one dose of Daptomycin between 2016 to 2021 are eligible.

Detailed Description

Not available

Study Timeline

• Study Start: 2018-06-01
• Study First Submitted: 2018-06-20
• Study First Submitted QC: 2018-07-04
• Study First Posted: 2018-07-17
• Primary Completion: 2021-01-01
• Study Completion: 2021-12-30
• Status Verified: 2022-07
• Last Update Submitted: 2022-07-22
• Last Update Posted: 2022-07-25

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 200

Inclusion Criteria

• Patient who received at least one dose of daptomycin

Exclusion Criteria

• No

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
mortality	30 days	death
Cure Rate	30 days	clinical and microbiological effectiveness

Secondary Outcome Measures

Name	Time	Method
Number of participants with treatment-related adverse events	30 days	organ dysfunction，allergy，creatine kinase levels，eosinophilic pneumonia，etc.

Trial Locations

Locations (1)

West China Hospital; 🇨🇳 Chengdu, Sichuan, China